In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Is BPC 157 Banned? Oral vs. Injectable Forms Explained RFK Jr. & claimed regenerative peptides like BPC 157 The Niche FDA's Overreach on Compounded Peptides FDA Moves to Reevaluate Several Peptides American Med Spa Association